Key result
Nitroderivative therapy failed to eradicate the parasite or change the progression of heart disease in chronic Chagas patients, with no significant difference in parasite load between treated and untreated groups.
Why the study?
Does nitroderivative therapy eradicate the parasite or prevent the progression of heart disease in patients with chronic Chagas disease?
Population
132 street cleaners from Brazil, including 91 with chronic Chagas disease and 41 uninfected male controls…
Comparison
Nitroderivative therapy administered for 20 to… vs Untreated chronic Chagas disease patients…
Design
Cohort, Randomized population sampling for screening, but treatment was not…
Follow-up
10 years
Authors
Loading...
Does not support nitroderivative use in chronic Chagas; leaves open confirmation by randomized trials.
RCT (n=132)
Single-blind
Randomized
No
Does nitroderivative therapy eradicate the parasite or prevent the progression of heart disease in patients with chronic Chagas disease?
Absolute Event Rate: 13.8% vs 20.1%
p-value: p=>0.05
Nitroderivative therapy fails to eradicate Trypanosoma cruzi or halt the progression of chronic Chagas heart disease over a 10-year follow-up period.
Lauria‐Pires et al. (2000) conducted an RCT in Chronic Chagas disease (n=132). Nitroderivatives (benznidazole or nifurtimox) vs. Untreated Chagas patients was evaluated on Parasite load (T. cruzi/ml of blood) by competitive PCR (p=>0.05). Nitroderivative therapy failed to eradicate the parasite or change the progression of heart disease in chronic Chagas patients, with no significant difference in parasite load between treated and untreated groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: